Esterification of Glycerol and Rosin Catalyzed by Irganox 1425: A Kinetic Comparison to the Thermal Process
Year: 2025
Type: article
Abstract: Rosin is a biomass-based chemical raw material employed in multiple industries: paper, polymers, coatings, adhesives, and more, while glycerol production has experienced a notable increment in recent decades due to it being an unavoidable by-product of the biodiesel industry. Rosin polyol esters are of high interest, and a potential route for the valorization of glycerol. In this work, we compare in detail the esterification routes of rosin triglycerides via classical, industrial thermal processes at 260–280 °C and similar processes catalyzed by Irganox 1425, a high-molecular-weight, multifunctional, phenolic, primary antioxidant produced by BASF and usually in rosin processes. Its chemical name is calcium bis(ethyl 3,5-di-tert-butyl-4-hydroxybenzylphosphonate). To this end, a novel RP-HPLC method provided us with a detailed description of the compositional evolution of the reacting media. These data have been the basis of a non-linear kinetic modeling procedure where we applied non-linear regression and numerical integration algorithms to determine the network of chemical reactions and the kinetic model of the rosin–glycerol esterification process. Furthermore, the comparison of such kinetic models and their parameters allows us to understand the kinetic effect of the addition of the homogeneous catalyst. The effect of Irganox 1425 results in a notable enhancement of the reaction rates, thus allowing for operation at lower temperatures and a reduction in side reactions as decarboxylation.
Source: Processes
DOI: 10.3390/pr13041096
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $2,896
Awards: G1288962084, G1647596629, G2450028142, G266215967, G2947653134, G3213247918, Enfermedad de McArdle: Aproximaciones terapeúticas 2D/3D basadas en el uso de iPSCs, G4760576710, G5310630539, G5764490426, Nuevos modelos humanos derivados de iPSCs para el estudio de la DOA+ y el desarrollo de terapias con antioxidantes naturales y exosomas. (O2DOA+iPS), G6581379718, G6806339617, G7080653532, G7274389268, G7864075302, Atrofia óptica dominante: iPSCs como modelo de enfermedad, mejora en el diagnóstico y aproximación a terapia, G991294861
OpenAlex ID: W4409213834